Table 3 Number of lesions on MRI in the ITT population, East Asian subgroup, Japanese subgroup, and Eastern European subgroup
ITT | East Asian subgroup | Japanese subgroup | Eastern European subgroup | |||||
|---|---|---|---|---|---|---|---|---|
Lesions, n (%) | Placebo n = 113 | DMFa n = 111 | Placebo n = 72 | DMFa n = 70 | Placebo n = 58 | DMFa n = 56 | Placebo n = 41 | DMFa n = 41 |
Number of new Gd+ lesions from weeks 12–24 | ||||||||
0 | 44 (39) | 81 (73) | 28 (39) | 55 (79) | 24 (41) | 45 (80) | 16 (39) | 26 (63) |
1–2 | 26 (23) | 23 (21) | 16 (22) | 10 (14) | 13 (22) | 8 (14) | 10 (24) | 13 (32) |
≥ 3 | 43 (38) | 7 (6) | 28 (39) | 5 (7) | 21 (36) | 3 (5) | 15 (37) | 2 (5) |
Number of new Gd+ lesions from baseline to week 24 | ||||||||
0 | 35 (31) | 58 (52) | 21 (29) | 38 (54) | 17 (29) | 30 (54) | 14 (34) | 20 (49) |
1–2 | 23 (20) | 37 (33) | 14 (19) | 25 (36) | 12 (21) | 21 (38) | 9 (22) | 12 (29) |
≥ 3 | 55 (49) | 16 (14) | 37 (51) | 7 (10) | 29 (50) | 5 (9) | 18 (44) | 9 (22) |
Number of new/newly enlarging T2 hyperintense lesions at week 24 | ||||||||
0 | 35 (31) | 44 (40) | 22 (31) | 29 (41) | 18 (31) | 23 (41) | 13 (32) | 15 (37) |
1–2 | 18 (16) | 47 (42) | 11 (15) | 26 (37) | 10 (17) | 22 (39) | 7 (17) | 21 (51) |
≥ 3 | 60 (53) | 20 (18) | 39 (54) | 15 (21) | 30 (52) | 11 (20) | 21 (51) | 5 (12) |